Aptar Digital Health, a global leader in digital health solutions (Software as a Medical Device (SaMD) and digital Patient Support Programs), connected devices and disease management, today announced a collaboration with SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors and innovative specialty delivery systems. The collaboration will extend SHL Medical’s connected device technologies by integrating Aptar Digital Health’s SaMD platform to provide comprehensive solutions to help patients on injectable therapies manage their disease.
As part of this collaboration, devices designed by SHL Medical, such as the Molly® Connected Cap – a smart retrofittable add-on for SHL Medical’s Molly® modular platform autoinjector – will benefit from Aptar Digital Health’s SaMD platform to enhance the patient experience by offering additional support during self-administration via a digital solution.
Aptar Digital Health’s SaMD platform offers digital health solutions adapted to the patient’s profile, disease state and treatment plan to empower them during their treatment journey. Through this partnership, SHL Medical will recommend Aptar Digital Health as a trusted digital partner that is recognized for its large portfolio of regulated digital health solutions and connected devices spanning multiple therapeutic areas and modes of administration. The partnership will leverage the capabilities of both companies to develop end-to-end solutions for the pharmaceutical industry that will support the enhancement of the patient experience during self-injection of innovative drugs such as GLP-1 for instance.
“Embarking on a self-injection therapy and adhering to a consistent injection schedule can pose a challenge to patients in being actively involved in their treatment journey,” stated Sai Shankar, President of Aptar Digital Health. “By joining forces with SHL Medical, a world-class leader in innovative drug delivery systems, we aim to positively and durably change the experience of patients who must self-inject regularly.”
“The increasing need for home-based treatments and the evolving healthcare landscape have created a need for collaborative innovation within the drug delivery industry,” added Ralph Howald, Chief Technical Officer at SHL Medical. “With our combined expertise, the partnership with Aptar Digital Health will serve as the first step in realizing a thoroughly-needed digital ecosystem for injectable drugs, starting with a digital transformation that will impact the end-to-end value chain in the future.”
With this partnership, Aptar Digital Health aims at reinforcing their portfolio of digital products and services to enhance the patient experience across the treatment journey. This offer spans from pre-prescription – direct-to-patient services, patient identification and activation – to support during and after prescription – companion apps, disease management platforms and targeted SaMDs to augment innovative drugs and contribute to improved patient adherence.
Download full Press Release.
